Behavioral Neuroscience – News and Features

Depressed patients may now benefit from a non-invasive treatment that stimulates the brain with a pulsing electromagnet.

A team of researchers has captured the 3D atomic models of a single transporter protein in each of its three main structural states.

A EUR 1.5 million BMBF grant will advance the H3 receptor antagonist programme through Phase I clinical studies.

A number of leading drug makers used this year's meeting of the American Academy of Neurology to present new data for promising pipeline candidates. Despite promising results, however, Datamonitor believes that the epilepsy drugs will struggle to find their place in the market. Moreover, the positive Phase II data for Baxter’s potential Alzheimer’s therapy Gammagard do not guarantee later success.

Earth Day offers an opportunity for reflection about our planet. Science and technology must play vital roles in both environmental protection and improvement of the human condition, and anyone who mindlessly, summarily rejects them is out of step with the occasion.

Newly published study supports the ability of Chronix’s serum DNA blood tests to monitor disease activity and response to treatment in multiple sclerosis.

The Phase II study will assess Serdaxin’s efficacy as a treatment for Parkinson’s disease in approximately 300 subjects.

Follows Recent Publication Showing Utility of Chronix’s Serum DNA Tests in Breast Cancer

Researchers have discovered a fifth genetic mutation associated with typical motor neurone disease, or amyotrophic lateral sclerosis, that has a similar pathological effect to certain genetic mutations revealed in earlier studies.

Researchers have found new clues that might help explain why some people are more susceptible to stress than others.